CFDE Data Portal | Search LOC102724701

	Label	Description
	LOC102724701 Gene (Entity type)	ENSG00000280145 - uncharacterized LOC102724701
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 4 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE140322 imatinib K-562 C.M.L. 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE140322 SRSF1 overexpression K-562 C.M.L. Imatinib 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE133933 fibulin-3 knockdown 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 cisplatin 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC102724701

ENSG00000280145 - uncharacterized LOC102724701

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE77108 saha 4 v 7 human up

A Gene Set from LINCS

GSE196343 metformin 1 v 0 human dn

A Gene Set from LINCS

GSE140322 imatinib K-562 C.M.L. 3 v 1 human dn

A Gene Set from LINCS

GSE140322 SRSF1 overexpression K-562 C.M.L. Imatinib 3 v 1 human dn

A Gene Set from LINCS

GSE133933 fibulin-3 knockdown 0 v 3 human up

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE229973 cisplatin 3 v 5 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.